Hon ANDREW LITTLE: Paxlovid is a five-day course of tablets that needs to be taken within five days of first developing symptoms of COVID-19. Access to Paxlovid will be tight to make sure it gets to the people who need it most. It will be prescribed by doctors with factors such as age, disability, and being immunocompromised taken into account. On Evusheld, this is a pre-exposure prophylactic treatment, as I said, and that can actually stop people developing COVID-19. Evusheld allows antibodies that provide protection against COVID-19 to be given directly to a patient and does not require a patient's immune system to create these antibodies. If approved by Medsafe, access criteria to Evusheld will be published by Pharmac.